EFA highlights urgent need for change and comprehensive European strategy to fight COPD

19 November 2009

The European Federation of Allergy and Airways Diseases Patients` Associations`(EFA) has launched a book comparing and analysing the situation of Chronic Obstructive Pulmonary Disease (COPD) in Europe for the first time from the patients' perspective. The Book highlights an urgent need to reduce the suffering and mortality from this disease, which will - if not tackled appropriately - be the third leading cause of death worldwide by 2030.

Launched to coincide with World COPD Day 2009, the 'EFA Book on COPD in Europe. Sharing and Caring,' represents an unprecedented collection of data on the quality of care, disease management, social and financial burden of COPD in Europe and highlights serious shortfalls across many measures.

The book sheds light on an 'underdiagnosed, undertreated and neglected disease.' It stresses that the misclassification and different definitions of COPD throughout Europe lead to underestimations of the actual impact of the disease. European Member of Parliament Catherine Stihler said: 'I highly commend the work of EFA. It is vital that people across Europe and the world are made aware of COPD. At least 44 million people across Europe are suffering from the disease, and the figure is set to rise each year.'

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical